Figure 2From: Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograftTumor microvessel density (MVD) and VEGF expression. (A) The VEGF and CD34 (marker for MVD) expression in SKOV-3 xenografts were detected by immunohistochemistry. (B) Tumor MVD and MOD of VEGF expression were calculated and the values were shown as percents of the control treatment. *, P < 0.01 compared with control. **, P < 0.01 compared with chA21 or trastuzumab alone.Back to article page